Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat

Cell Biochemistry and Function

Volumn 30, Issue 4, 2012, Pages 279-285

  Xia, Xiao dong ^a   Xu, Zheng jie ^b   Hu, Xiao guang ^a   Wu, Cheng yun ^a   Dai, Yuan rong ^a   Yang, Lei ^b  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hypercapnia; Hypoxia; Inducible nitric oxide synthase; Pulmonary hypertension; Soluble guanylate cyclase

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ALPHA1; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; BODY WEIGHT; CHRONIC HYPOXIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HYPERCAPNIA; HYPERCAPNIC PULMONARY HYPERTENSION; HYPOXIA; LUNG PARENCHYMA; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; UPREGULATION;

ANIMALS; ANOXIA; CYCLIC GMP; GUANYLATE CYCLASE; HEART VENTRICLES; HYPERCAPNIA; HYPERTENSION, PULMONARY; LUNG; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; UP-REGULATION; VENTRICULAR FUNCTION;

RATTUS;

EID: 84862830654     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2796     Document Type: Article

References (35)

1. Xue C, Rengasamy A, Le Cras TD, et al. Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am J Physiol 1994; 267(6 Pt 1): L667-L678.
2. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329(27): 2002-2012.
3. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000; 80(4): 1337-1372.
4. Poulos TL. Soluble guanylate cyclase. Curr Opin Struct Biol 2006; 16(6): 736-743.
5. Derbyshire ER, Marletta MA. Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol 2009; 191: 17-31.
6. Fagan KA, Morrissey B, Fouty BW, et al. Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension. Respir Res 2001; 2(5): 306-313.
7. Howell K, Ooi H, Preston R, McLoughlin P. Structural basis of hypoxic pulmonary hypertension: the modifying effect of chronic hypercapnia. Exp Physiol 2004; 89(1): 66-72.
8. Kantores C, McNamara PJ, Teixeira L, et al. Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat. Am J Physiol Lung Cell Mol Physiol 2006; 291(5): L912-L922.
9. Ooi H, Cadogan E, Sweeney M, Howell K, O'Regan RG, McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2000; 278(2): H331-H338.
10. Chovanec M, Novotná J, Wilhelm J, Hampl V, Vízek M, Herget J. Hypercapnia attenuates hypoxic pulmonary hypertension by inhibiting lung radical injury. Physiol Res 2009; 58(2): S79-S85.
11. Zuo Z, Johns RA. Halothane, enflurane, and isoflurane do not affect the basal or agonist-stimulated activity of partially isolated soluble and particulate guanylyl cyclases of rat brain. Anesthesiology 1995; 83(2): 395-404.
12. Chuang IC, Dong HP, Yang RC, et al. Effect of carbon dioxide on pulmonary vascular tone at various pulmonary arterial pressure levels induced by endothelin-1. Lung 2010; 188(3): 199-207.
13. Xue C, Johns RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension 1996; 28(5): 743-753.
14. Cadogan E, Hopkins N, Giles S, Bannigan JG, Moynihan J, McLoughlin P. Enhanced expression of inducible nitric oxide synthase without vasodilator effect in chronically infected lungs. Am J Physiol 1999; 277(3 Pt 1): L616-L627.
15. Teng X, Li D, Catravas JD, Johns RA. C/EBP-beta mediates iNOS induction by hypoxia in rat pulmonary microvascular smooth muscle cells. Circ Res 2002; 90(2): 125-127.
16. Shirai M, Pearson JT, Shimouchi A, et al. Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries. Br J Pharmacol 2003; 139(5): 899-910.
17. Liu Y, Chacko BK, Ricksecker A, et al. Modulatory effects of hypercapnia on in vitro and in vivo pulmonary endothelial-neutrophil adhesive responses during inflammation. Cytokine 2008; 44(1): 108-117.
18. Skoumalová A, Herget J, Wilhelm J. Hypercapnia protects erythrocytes against free radical damage induced by hypoxia in exposed rats. Cell Biochem Funct 2008; 26(7): 801-807.
19. Kacimi R, Long CS, Karliner JS. Chronic hypoxia modulates the interleukin-1beta-stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation 1997; 96(6): 1937-1943.
20. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999; 1411(2-3): 334-350.
21. Bloch KD, Filippov G, Sanchez LS, Nakane M, de la Monte SM. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol 1997; 272(3 Pt 1): L400-L406.
22. Berkenbosch JW, Baribeau J, Perreault T. Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2000; 278(2): L276-L283.
23. Williams JM, White CR, Chang MM, Injeti ER, Zhang L, Pearce WJ. Chronic hypoxic decreases in soluble guanylate cyclase protein and enzyme activity are age dependent in fetal and adult ovine carotid arteries. J Appl Physiol 2006; 100(6): 1857-1866.
24. Hassoun PM, Filippov G, Fogel M, et al. Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2004; 30(6): 908-913.
25. Li D, Laubach VE, Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 2001; 281(2): L369-L376.
26. Ujiie K, Hogarth L, Danziger R, et al. Homologous and heterologous desensitization of a guanylyl cyclase-linked nitric oxide receptor in cultured rat medullary interstitial cells. J Pharmacol Exp Ther 1994; 270(2): 761-767.
27. Papapetropoulos A, Marczin N, Mora G, Milici A, Murad F, Catravas JD. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-elevating agents. Hypertension 1995; 26(4): 696-674.
28. Liu H, Force T, Bloch KD. Nerve growth factor decreases soluble guanylate cyclase in rat pheochromocytoma PC12 cells. J Biol Chem 1997; 272(9): 6038-6043.
29. Takata M, Filippov G, Liu H, et al. Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001; 280(2): L272-L278.
30. Papapetropoulos A, Cziraki A, Rubin JW, Stone CD, Catravas JD. cGMP accumulation and gene expression of soluble guanylate cyclase in human vascular tissue. J Cell Physiol 1996; 167(2): 213-221.
31. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997; 100(4): 942-948.
32. Wu BN, Chen CW, Liou SF, Yeh JL, Chung HH, Chen IJ. Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: the involvement of soluble guanylate cyclase and protein kinase G. Mol Pharmacol 2006; 70(3): 977-985.
33. Tzao C, Nickerson PA, Russell JA, Noble BK, Steinhorn RH. Paracrine role of soluble guanylate cyclase and type III nitric oxide synthase in ovine fetal pulmonary circulation: a double labeling immunohistochemical study. Histochem Cell Biol 2003; 119(2): 125-130.
34. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002; 137(8): 1187-1194.
35. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997; 283(2): 619-624.